In DLBCL, several AI techniques were used for multidimensionality reduction to predict the overall survival of the patients. As a result, two markers were highlighted, programmed cell death1 ligand 1 (PD-L1/CD274) and IKAROS, which were later tested by immunohistochemistry in an independent series of cases. The gene discussed is IKZF1; the disease is diffuse large B-cell lymphoma.